Buck Scientist Engineers Living Immune Cells to Fight Alzheimer's Disease
Chaska Walton is building programmable immune cells that detect and treat multiple Alzheimer's pathologies simultaneously — a potential paradigm shift.
Summary
Researcher Chaska Walton at the Buck Institute is developing engineered immune cells that act like living drug-delivery systems inside the brain. Funded by a rare $2.4 million NIH Transformative Research Award — one of only nine granted nationally — Walton's work focuses on programming immune cells to detect Alzheimer's-specific pathology and respond by synthesizing and releasing therapeutic compounds on-site. Rather than targeting a single disease mechanism, this approach aims to address multiple overlapping pathologies simultaneously. Walton's background spans psychology, neuroscience, and synthetic biology, and their earlier research challenged dogma by showing mature neurons can re-enter the cell cycle. The work represents a convergence of neuroscience, synthetic biology, and translational medicine with the goal of making neurodegeneration a treatable, not inevitable, condition.
Detailed Summary
Alzheimer's disease remains one of the most complex and treatment-resistant conditions in medicine, largely because it involves multiple interacting pathologies rather than a single fixable defect. Researcher Chaska Walton at the Buck Institute is tackling this challenge with a bold approach: engineering living immune cells to serve as programmable, on-demand therapeutic agents inside the body.
Walton's project, backed by a $2.4 million NIH Transformative Research Award — among only nine awarded nationally — centers on CAR-Treg cells and smart cell delivery platforms. These engineered immune cells are designed to detect specific molecular signatures of Alzheimer's pathology and, upon detection, synthesize and release targeted therapeutic drugs directly at the site of damage. The concept mirrors science fiction's nanobots but uses biology instead of machinery.
The core insight driving this work is that Alzheimer's resembles a cascade of compounding failures — like driving a car with a flat tire until the entire vehicle breaks down. Treating one pathology at a time may never be sufficient. Walton's system is designed to respond dynamically to multiple disease states, potentially offering a more comprehensive intervention than any single drug could achieve.
Walton's earlier research at the Cajal Institute in Madrid challenged established neuroscience by demonstrating that mature neurons can re-enter the cell cycle, a finding that opened new questions about neuronal vulnerability and aging. That foundational work informs their current translational focus at the intersection of neuroscience and synthetic biology.
While this research is still in development and has not yet reached clinical trials, the NIH recognition signals strong scientific credibility. The approach could eventually influence how medicine addresses not just Alzheimer's but other complex, multi-pathology diseases of aging. For longevity-focused readers, this represents a frontier where engineered biology may one day make neurodegeneration a preventable or reversible condition rather than an accepted fate.
Key Findings
- Walton received one of only 9 NIH Transformative Research Awards nationally, totaling $2.4 million for Alzheimer's cell therapy.
- Engineered immune cells are programmed to detect Alzheimer's pathology and synthesize therapeutic drugs on-site.
- CAR-Treg and smart cell delivery platforms aim to address multiple Alzheimer's disease pathologies simultaneously.
- Earlier research showed mature neurons can re-enter the cell cycle, challenging long-held neuroscience dogma.
- Neurodegeneration is framed as a biological process that can be engineered and reversed, not an inevitable aging outcome.
Methodology
This is a profile/interview article published by the Buck Institute, a leading aging research institution. It is not a peer-reviewed study but a researcher spotlight with institutional credibility. Evidence basis is the researcher's described work and NIH award recognition, not published trial data.
Study Limitations
No primary research paper or clinical trial data is cited in this article; it is a narrative profile. The therapy is in development and has not been tested in humans. Readers should seek published studies from Walton's lab for evidence-based assessment of efficacy and safety.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.